BioSpace News Archive

Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter 2020 financial results Friday, May 8, 2020

Repotrectinib Demonstrated Potent Antitumor Activity in Intracranial Preclinical Tumor Model

Groundbreaking Technology Provides Long Term Protection From Problematic Bacteria & Viruses

New research from Prime Therapeutics LLC (Prime), a pharmacy benefit manager (PBM) serving more than 30 million members nationally, found that among commercially insured members with asthma, the number of members who utilized biologics nearly doubled in a 2.5 year span, as did the amount of spending on those medications.

Agendia®, Inc., a world leader in precision oncology for breast cancer, announced today that Translational Cancer published long term analytical performance characteristics of the 80-gene BluePrint® molecular subtyping ass

MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today the addition of Kelly Vaillant as Director, Global Transparency Strategy and Compliance.

Accelerated Enrollment Solutions (AES), a business of PPD, Inc. (Nasdaq:PPD), has launched a new program to help biopharmaceutical companies maintain business continuity during the global COVID-19 pandemic by transferring clinical trial patients to AES’ dedicated research sites from other research facilities impacted by the coronavirus crisis.

Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced the pricing of an underwritten public offering of 4,117,650 shares of its common stock at a public offering price of $17.00 per share.

Drug also shows promise for helping to alleviate lung and cardiac symptoms associated with COVID-19

BioSig Technologies, Inc. (NASDAQ: BSGM) today announced that its subsidiary ViralClear Pharmaceuticals, Inc. updated its clinical development program for Vicromax™ (merimepodib, or MMPD) as a treatment for COVID-19.